On December 2, 2024, NeuroSense Therapeutics entered into a Securities Purchase Agreement with a single investor and CEO Alon Ben-Noon for a $5 million private placement. The offering includes 2,343,729 ordinary shares, 1,656,271 pre-funded warrants, and 8,000,000 ordinary warrants. The purchase price per share and accompanying warrants is $1.25, with gross proceeds expected to be approximately $5 million.The proceeds will support the clinical development of PrimeC for ALS, research for Alzheimer's and Parkinson's diseases, and other corporate purposes. The offering is exempt from registration under the Securities Act, relying on Section 4(a)(2) and Regulation D. The company will file a registration statement for resale of the securities.The private placement is expected to close in December 2024, with proceeds delivered in two tranches. NeuroSense aims to advance its lead product candidate and explore new therapeutic opportunities.

On December 2, 2024, NeuroSense Therapeutics entered into a Securities Purchase Agreement with a single investor and CEO Alon Ben-Noon for a $5 million private placement. The offering includes 2,343,729 ordinary shares, 1,656,271 pre-funded warrants, and 8,000,000 ordinary warrants. The purchase price per share and accompanying warrants is $1.25, with gross proceeds expected to be approximately $5 million.The proceeds will support the clinical development of PrimeC for ALS, research for Alzheimer's and Parkinson's diseases, and other corporate purposes. The offering is exempt from registration under the Securities Act, relying on Section 4(a)(2) and Regulation D. The company will file a registration statement for resale of the securities.The private placement is expected to close in December 2024, with proceeds delivered in two tranches. NeuroSense aims to advance its lead product candidate and explore new therapeutic opportunities.